# FDA 483 - K.C. Pharmaceuticals, Inc. - February 13, 2023

Source: https://www.keypedia.com/records/483/kc-pharmaceuticals-inc/afc1f21f-b210-44d4-b330-8d4de530e587

> FDA 483 for K.C. Pharmaceuticals, Inc. on February 13, 2023. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: K.C. Pharmaceuticals, Inc.
- Inspection Date: 2023-02-13
- Product Type: Drugs
- Office Name: Los Angeles District Office
- Summary: The content of the FDA 483 document, specifically pages 18 through 27, was not provided. As such, it is impossible to generate a concise summary detailing the company name, inspection dates, main violations/issues, regulatory framework, or required actions as requested. Please provide the full text of the document to enable accurate summarization.

## Related Documents

- [483 - 2017-11-16](https://www.keypedia.com/records/483/kc-pharmaceuticals-inc/eedfcc86-c1ea-45ab-ba87-44cf6a3078fc)

## Related Officers

- [Consumer Safety Officer (Inspector)](https://www.keypedia.com/people/christopher-r-czajka/42defbf3-ea06-4090-8d51-7da2b07d9e84)
- [investigator](https://www.keypedia.com/people/amir-alavi/d7179128-eb3f-489e-97cf-e2c5e5539a00)

Company: https://www.keypedia.com/companies/kc-pharmaceuticals-inc/19388e8b-b402-4916-aecd-2eb637193aa7

Office: https://www.keypedia.com/offices/los-angeles-district-office/edcf1dfe-596a-43b8-8df4-07d9cd94763b